Relapse, defined as the recurrence of signs or symptoms of GCA or as an elevation of CRP of 10 mg/L or more attributable to GCA, is determined using the GCA relapse assessment as judged by the treating rheumatologist. This evidence concerns the gene CRP and temporal arteritis.